LYHLTW:SW:SW-Lyxor MSCI World Health Care TR UCITS ETF - C-USD USD (USD)

ETF | Others |

Last Closing

USD 551.8

Change

-4.40 (-0.79)%

Market Cap

USD 0.10B

Volume

10.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.07 (-0.54%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.03 (-0.12%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.29 (-1.05%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+2.00 (+0.04%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-7.00 (-0.42%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-1.00 (-0.05%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.12 (+0.16%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.96 (+0.83%)

USD 130,595.12B

ETFs Containing LYHLTW:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.17% 63% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.17% 63% D 64% D
Trailing 12 Months  
Capital Gain 21.56% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.56% 62% D 63% D
Trailing 5 Years  
Capital Gain 73.55% 86% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.55% 86% B+ 85% B
Average Annual (5 Year Horizon)  
Capital Gain 9.04% N/A N/A 79% B-
Dividend Return 9.04% N/A N/A 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.01% N/A N/A 43% F
Risk Adjusted Return 90.29% N/A N/A 98% N/A
Market Capitalization 0.10B 30% F 26% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.